Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company’s IPO at the New York Stock Exchange (NYSE), May 4, 2023.
Brendan McDermid | Reuters
Tylenol maker Kenvue’s CEO and board member Thibaut Mongon has stepped down, it said on Monday and named company director Kirk Perry as interim chief executive.
The company, which was spun off from Johnson & Johnson in 2023, has been under pressure from activist investors to boost performance, particularly in its skin-health and beauty unit, which includes brands such as Neutrogena and Aveeno.
“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the company’s portfolio and how it operates,” said board chair Larry Merlo.
Perry has previously spent 23 years with Procter & Gamble. He most recently served as president and CEO of Circana, a global provider of technology, data and predictive analytics for the consumer, retail and media sectors.
